NCT06647810

A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood

Relative Bioavailability of Two Different BI 690517 Formulations as Well as the Effect of Multiple Doses of Probenecid on the Single Dose Pharmacokinetics of BI 690517 Following Oral Administration in Healthy Male and Female Subjects (a Randomised, Open-label, Three-way Crossover Trial)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This trial aims to test how two different formulations of BI 690517 are taken up by the body and how probenecid influences the amount of BI 690517 in the blood.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 690517 formulation 1	BI 690517 formulation 1
DRUG	BI 690517 formulation 2	BI 690517 formulation 2
DRUG	Probenecid	Probenecid

Timeline

• Start date: 2024-11-13
• Primary completion: 2024-12-12
• Completion: 2025-01-07
• First posted: 2024-10-18
• Last updated: 2025-01-09

Locations

1 site across 1 country: Germany